drugset / Trial / NCT01434888

Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops

NCT01434888

Phase 1 Completed 15 enrolled Santen Inc.
RandomizedCrossoverTriple-blindBasic science

Summary

The objective of this study is to investigate the pharmacokinetics, safety and tolerability of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (FDC) to those of preservative-free tafluprost 0.0015% and timolol 0.5% eye drops in healthy volunteers.

Timeline

Start
2011-09
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops Unknown 0.0015 % Other
Subject Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops Unknown 0.5 % Other
Comparator Tafluprost Other / unclassified 0.0015 % Other
Comparator Timolol Other / unclassified 0.5 % Other

Indications

No indication recorded.